Evidence map›Paper›PMID 37868689›Full record

ArticleOncoimmunology2023

Niklas Klümper, Lennert Wüst, Jonas Saal, Damian J Ralser, Romina Zarbl, Jonas Jarczyk, Johannes Breyer, Danijel Sikic, Bernd Wullich, Christian Bolenz and 10 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 1 country.

Niklas KlümperDepartment of Urology and Pediatric Urology, University Medical Center Bonn (UKB), Bonn, Germany.
Lennert WüstCenter for Integrated Oncology, Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Germany.
Jonas SaalCenter for Integrated Oncology, Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Germany.
Damian J RalserInstitute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, Germany.
Romina ZarblCenter for Integrated Oncology, Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Germany.
Jonas JarczykDepartment of Urology and Urosurgery, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Johannes BreyerDepartment of Urology, Caritas Hospital St. Josef, University of Regensburg, Regensburg, Germany.
Danijel SikicCenter for Integrated Oncology, Bavarian Center for Cancer Research (Bayerisches Zentrum für Krebsforschung, BZKF), Erlangen, Germany.
Bernd WullichCenter for Integrated Oncology, Bavarian Center for Cancer Research (Bayerisches Zentrum für Krebsforschung, BZKF), Erlangen, Germany.
Christian BolenzDepartment of Urology, University Hospital Ulm, Ulm, Germany.
Florian RoghmannDepartment of Urology, Ruhr-University Bochum, Herne, Germany.
Michael HölzelInstitute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, Germany.
Manuel RitterDepartment of Urology and Pediatric Urology, University Medical Center Bonn (UKB), Bonn, Germany.
Sebastian StriethCenter for Integrated Oncology, Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Germany.
Arndt HartmannCenter for Integrated Oncology, Bavarian Center for Cancer Research (Bayerisches Zentrum für Krebsforschung, BZKF), Erlangen, Germany.
Philipp ErbenDepartment of Urology and Urosurgery, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Ralph M WirtzCenter for Integrated Oncology, STRATIFYER Molecular Pathology GmbH, Cologne, Germany.
Jennifer LandsbergCenter for Integrated Oncology, Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Germany.
Dimo DietrichCenter for Integrated Oncology, Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Germany.ORCID 0000-0001-9794-7927
Markus EcksteinCenter for Integrated Oncology, Bavarian Center for Cancer Research (Bayerisches Zentrum für Krebsforschung, BZKF), Erlangen, Germany.
Friedrich-Alexander-Universität Erlangen-Nürnberg · DEUniversity Hospital Bonn · DEHeidelberg University · DERuhr University Bochum · DEUniversity Hospital Ulm · DEUniversity of Regensburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PD-L1 status assessed by immunohistochemistry (IHC) has failed to reliably predict outcomes for patients with metastatic urothelial carcinoma (mUC) on immune checkpoint blockade (ICB).

Indexed as

Carcinoma, Transitional CellImmunotherapyPromoter Regions, GeneticUrinary Bladder NeoplasmsB7-H1 AntigenDNA MethylationHumansInterferon-gammaB7-H1 AntigenCD274 protein, humanInterferon-gammabiomarkerbladder cancerCD274DNA methylationimmune checkpoint blockadeimmunotherapymetastatic urothelial carcinomaPD-L1promoter methylation

Identifiers

PMID37868689
PMCPMC10588513
OpenAlexW4387781272

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.